These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2554602)

  • 1. Effect of N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl- L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice.
    Ishihara C; Iida J; Mizukoshi N; Yamamoto N; Yamamoto K; Kato K; Azuma I
    Vaccine; 1989 Aug; 7(4):309-13. PubMed ID: 2554602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
    Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
    Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
    Ishihara C; Yamamoto K; Hamada N; Azuma I
    Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of Sendai virus growth by treatment with N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine in mice.
    Ishihara C; Mizukoshi N; Iida J; Kato K; Yamamoto K; Azuma I
    Vaccine; 1987 Dec; 5(4):295-301. PubMed ID: 2448969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
    Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
    Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenicity study of muroctasin.
    Yamaguchi F; Hattori H; Wagai N; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine.
    Matsumoto K; Otani T; Une T; Osada Y; Ogawa H; Azuma I
    Infect Immun; 1983 Mar; 39(3):1029-40. PubMed ID: 6341226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
    Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
    Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutagenicity studies of muroctasin.
    Shimada H; Hattori C; Sato T
    Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of plasma fibronectin production in mice by muroctasin.
    Endo N; Okuda T; Osada Y; Zen-Yoji H
    Arzneimittelforschung; 1988 Jul; 38(7A):997-8. PubMed ID: 3190806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
    Nagao S; Sato K; Osada Y
    Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific binding sites of muroctasin on murine macrophages.
    Akasaki M; Masayasu H; Tsukada W; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):978-80. PubMed ID: 3190804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of host-defense mechanism with synthetic adjuvants and recombinant cytokines against viral infection in mice.
    Azuma I; Ishihara C; Iida J; Yoo YC; Yoshimatsu K; Arikawa J
    Adv Exp Med Biol; 1992; 319():253-63. PubMed ID: 1329443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotransformation of muroctasin in mice.
    Matsubayashi K; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):1015-8. PubMed ID: 3190793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice.
    Nakajima R; Ishida Y; Yamaguchi F; Otani T; Ono Y; Nomura M; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):986-92. PubMed ID: 3263871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs.
    Ikeda S; Negishi T; Nishimura C
    Antiviral Res; 1985 Aug; 5(4):207-15. PubMed ID: 2412489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.